NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free XPH Stock Alerts $39.59 -0.30 (-0.75%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$39.59▼$39.9150-Day Range$39.59▼$45.5552-Week Range$34.67▼$45.62Volume44,777 shsAverage Volume44,173 shsMarket Capitalization$193.99 millionAssets Under Management$195.41 millionDividend Yield1.69%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get SPDR S&P Pharmaceuticals ETF alerts: Email Address About SPDR S&P Pharmaceuticals ETFSPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XPH ETF News HeadlinesMarch 30, 2024 | finance.yahoo.comSPDR S&P Pharmaceuticals ETF (XPH)March 28, 2024 | seekingalpha.comXPH: A More Balanced Way To Get Exposure To PharmaceuticalsApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.February 16, 2024 | wsj.comSPDR S&P Pharmaceuticals ETFFebruary 5, 2024 | usatoday.comS&P 500 (SPX) today: Catalent Inc is a top mover, up 10%December 23, 2023 | benzinga.comSPDR S&P Pharmaceuticals ETF (ARCA:XPH), Quotes and News SummaryDecember 18, 2023 | msn.comSPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1744November 6, 2023 | marketwatch.comWhy the S&P 500 ETF’s rare triple ‘gap ups’ isn’t a buy signalApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.October 29, 2023 | investing.comXPH ETF Stock Price HistorySee More Headlines Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings42 Fund Statistics Assets Under Management$195.41 million Average Daily Volume$43,324.50 Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume2 Put Options1 Call Options1 Short Interest345,900 shs Miscellaneous Outstanding Shares4,900,000Beta0.87 Creation Unit50,000 Creation Fee$250.00 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.35%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.35%0.60%0.60%0.58%0.58% SPDR S&P Pharmaceuticals ETF (XPH) Holdings & ExposureTop 10 XPH HoldingsMerck & Co., Inc.(NYSE:MRK)Holding Weight: 4.81%Perrigo(NYSE:PRGO)Holding Weight: 4.79%Catalent(NYSE:CTLT)Holding Weight: 4.74%Intra-Cellular Therapies(NASDAQ:ITCI)Holding Weight: 4.74%Eli Lilly and Company(NYSE:LLY)Holding Weight: 4.69%Organon & Co.(NYSE:OGN)Holding Weight: 4.66%Axsome Therapeutics(NASDAQ:AXSM)Holding Weight: 4.57%Pfizer(NYSE:PFE)Holding Weight: 4.56%Jazz Pharmaceuticals(NASDAQ:JAZZ)Holding Weight: 4.55%Royalty Pharma(NASDAQ:RPRX)Holding Weight: 4.50%XPH Sector ExposureXPH Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHDirexion Daily Healthcare Bull 3x SharesNYSEARCA:CUREInvesco Biotechnology & Genome ETFNYSEARCA:PBEInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHSimplify Health Care ETFNYSEARCA:PINKInstitutional OwnershipPNC Financial Services Group Inc.Sold 11,427 shares on 3/22/2024Ownership: 0.528%Citadel Advisors LLCSold 4,700 shares on 2/15/2024Ownership: 0.000%GTS Securities LLCBought 12,162 shares on 2/15/2024Ownership: 0.232%Royal Bank of CanadaSold 22,954 shares on 2/14/2024Ownership: 0.503%Cetera Advisor Networks LLCBought 11,347 shares on 2/13/2024Ownership: 0.216%View All Institutional Transactions XPH ETF - Frequently Asked Questions How have XPH shares performed in 2024? SPDR S&P Pharmaceuticals ETF's stock was trading at $41.62 at the beginning of the year. Since then, XPH stock has decreased by 4.9% and is now trading at $39.59. View the best growth stocks for 2024 here. What does XPH invest in? SPDR S&P Pharmaceuticals ETF is a equity fund issued by SSgA. XPH focuses on health care investments and follows the S&P Pharmaceuticals Index. The fund's investments total to approximately $195.41 million assets under management. What stocks does SPDR S&P Pharmaceuticals ETF hold? XPH invests in 42 holdings. Some of the stocks in their portfolio include Merck & Co., Inc. (MRK), Perrigo (PRGO), Catalent (CTLT), Intra-Cellular Therapies (ITCI), Eli Lilly and Company (LLY), Organon & Co. (OGN), Axsome Therapeutics (AXSM), Pfizer (PFE), Jazz Pharmaceuticals (JAZZ) and Royalty Pharma (RPRX). What is the management fee for SPDR S&P Pharmaceuticals ETF? SPDR S&P Pharmaceuticals ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XPH is 0.35%. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Pharmaceuticals ETF investors own include Pfizer (PFE), Bank of America (BAC), Micron Technology (MU), Broadcom (AVGO), Chevron (CVX), DocuSign (DOCU), SPDR Gold Shares (GLD), International Business Machines (IBM), JPMorgan Chase & Co. (JPM) and AT&T (T). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:XPH) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldIRS Loophole Gives Americans An Escape From InflationBirch GoldHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.